My position on a CR in the next 3-6 months is that I personally don't want one.
If you're asking what I think the likelihood is that there will be a CR in the next 3-6 months, well I think that's a question that any answer at this stage is merely a guess. Once the December 4C is released we'll have a proper picture of the impact of Limepay, whether that's a net +ve or a net -ve, and also whether the revenue from the Spenda customers has grown meaningfully from the September 1/4.
The September 4C showed the net operating cash deficit of $2.132m (i.e. excluding additional cash deployed in the lending and cash received from Limepay acquisition completion). Therefore, if the December 1/4 can close that operating cash deficit to $1m, then the cash runway has doubled. But if the operating cash deficit does not materially decrease, then a CR becomes much more likely, although I'd much rather the company acquired a debt facility for working capital rather than doing another CR at these prices.
- Forums
- ASX - By Stock
- SPX
- DAILY VOLUME UPDATE
SPX
spenda limited
Add to My Watchlist
9.09%
!
0.6¢

DAILY VOLUME UPDATE, page-439
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
0.6¢ |
Change
0.001(9.09%) |
Mkt cap ! $32.30M |
Open | High | Low | Value | Volume |
0.6¢ | 0.7¢ | 0.6¢ | $16.71K | 2.780M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 1363135 | 0.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.7¢ | 17554228 | 28 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 1447135 | 0.006 |
51 | 24939523 | 0.005 |
8 | 15700000 | 0.004 |
9 | 26100000 | 0.003 |
5 | 17000002 | 0.002 |
Price($) | Vol. | No. |
---|---|---|
0.007 | 17474228 | 27 |
0.008 | 4741717 | 26 |
0.009 | 11710538 | 17 |
0.010 | 846836 | 6 |
0.011 | 527004 | 4 |
Last trade - 13.36pm 27/06/2025 (20 minute delay) ? |
Featured News
SPX (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online